Inactive Instrument

Highlights ONCODESIGN

Equities

ALONC

FR0011766229

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund	19/22/19	MT
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris	05/22/05	MT
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	05/22/05	CI
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	05/22/05	CI
Euronext Paris authorises the listing of Oncodesign Precision Medicine shares on Euronext Access + in connection with the allocation of OPM shares to Oncodesign shareholders	29/22/29	AQ
Oncodesign Unit Gains Approval To List On Euronext Access + In Paris	29/22/29	MT
Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine.	28/22/28	CI
Oncodesign Société Anonyme Announces Planned Separation of Its Two Business Areas	01/22/01	CI
Oncodesign Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	07/22/07	CI
Sengine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors	08/22/08	CI
Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired.	24/21/24	CI
Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease	04/21/04	CI
Oncodesign : Starts R&D Deal with TiumBio for Fibrosis Drug Candidates	21/21/21	MT
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates	21/21/21	CI
Oncodesign Announces Unaudited Consolidated Sales Results for the Half Year Ended June 30, 2021	16/21/16	CI
Global markets live: AT&T, American Airlines, Biogen, Netflix, ABB...	22/21/22
Oncodesign Announces a Strategic Collaboration Agreement with Covalab	28/21/28	CI
Global markets live: Siemens, BHP Group, Visa, JP Morgan Chase, Proximus...	24/21/24
Oncodesign Provides Update on Its Progress on RIPK2	24/21/24	CI
Servier and Oncodesign Announce the Selection of a Preclinical Candidate as Part of its Collaboration Targeting New Treatments for Parkinson’s Disease	14/21/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ONCODESIGN

Equities

ALONC

FR0011766229

Highlights

Filters